Research programme: norovirus vaccine - Daiichi Sankyo/UMN Pharma

Drug Profile

Research programme: norovirus vaccine - Daiichi Sankyo/UMN Pharma

Latest Information Update: 19 Feb 2014

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; UMN Pharma
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Norovirus infections

Most Recent Events

  • 14 Feb 2014 Daiichi Sankyo and UMN Pharma agree to co-develop norovirus vaccine in Japan for Norovirus infections
  • 14 Feb 2014 Early research in Norovirus infections (prevention) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top